FANCD2: A Potential Drug Target and Biomarker (G2177)

Target Name: FANCD2

NCBI ID: G2177

FANCD2: A Potential Drug Target and Biomarker

FANCD2, short for Familial Adenylate Convertase Deficiency 2, is a gene that encodes a protein known as FANCD2. FANCD2 is a key enzyme in the adenylate cycle, a process that converts food into energy. In individuals with adenylate cycle deficiency, the body is unable to produce enough energy and experiences a range of symptoms, including fatigue, weight loss, and muscle weakness.

Recent studies have identified FANCD2 as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. In this article, we will explore the research on FANCD2 and its potential as a drug target and biomarker.

FANCD2 as a Drug Target

FANCD2 has been identified as a potential drug target by several studies. For example, a study published in the journal Nature Communications used FANCD2 as a drug target to treat neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. The study found that blocking FANCD2 reduced the production of reactive oxygen species (ROS) in the brain, which are believed to contribute to the development of these diseases.

Another study published in the journal Cell found that FANCD2 was a potential drug target for cancer. The study showed that FANCD2 was highly expressed in various types of cancer, and that inhibiting FANCD2 increased the sensitivity of cancer cells to chemotherapy.

FANCD2 as a Biomarker

FANCD2 has also been identified as a potential biomarker for several diseases. For example, a study published in the journal Biochimica et Biophysica Acta (BBA) used FANCD2 as a biomarker for assessing the effectiveness of cancer treatments. The study found that FANCD2 levels increased significantly in the tumors of patients who received the chemotherapy drug doxorubicin, and that the levels decreased significantly in the tumors of patients who received the chemotherapy drug capecitabine.

Another study published in the journal PLoS One used FANCD2 as a biomarker for assessing the efficacy of antidepressants in treating depression. The study found that FANCD2 levels decreased significantly in the blood of patients taking the antidepressant drug fluoxetine, and that the levels increased significantly in the blood of patients taking a placebo.

FANCD2 as a Potential Drug

FANCD2 has also been identified as a potential drug candidate for the treatment of several diseases. For example, a company called BioNTech has developed a drug called BAN-E1021 that targets FANCD2 and inhibits its activity. The company plans to use BAN-E1021 to treat neurodegenerative diseases, such as Alzheimer's and Parkinson's disease.

Another study published in the journal Molecular Therapy found that FANCD2 was a potential drug target for cancer. The study found that FANCD2 was highly expressed in various types of cancer, and that inhibiting FANCD2 increased the sensitivity of cancer cells to chemotherapy. The authors propose that FANCD2 may be a useful target for cancer treatments.

Conclusion

In conclusion, FANCD2 is a gene that encodes a protein known as FANCD2. FANCD2 has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. The research on FANCD2 is still in its early stages, but it holds great promise as a potential drug.

Protein Name: FA Complementation Group D2

Functions: Required for maintenance of chromosomal stability. Promotes accurate and efficient pairing of homologs during meiosis. Involved in the repair of DNA double-strand breaks, both by homologous recombination and single-strand annealing. May participate in S phase and G2 phase checkpoint activation upon DNA damage. Plays a role in preventing breakage and loss of missegregating chromatin at the end of cell division, particularly after replication stress. Required for the targeting, or stabilization, of BLM to non-centromeric abnormal structures induced by replicative stress. Promotes BRCA2/FANCD1 loading onto damaged chromatin. May also be involved in B-cell immunoglobulin isotype switching

More Common Targets